1. Home
  2. BEAM vs LION Comparison

BEAM vs LION Comparison

Compare BEAM & LION Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • LION
  • Stock Information
  • Founded
  • BEAM 2017
  • LION 1997
  • Country
  • BEAM United States
  • LION United States
  • Employees
  • BEAM N/A
  • LION N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • LION Movies/Entertainment
  • Sector
  • BEAM Health Care
  • LION Consumer Discretionary
  • Exchange
  • BEAM Nasdaq
  • LION Nasdaq
  • Market Cap
  • BEAM 1.6B
  • LION 1.6B
  • IPO Year
  • BEAM 2020
  • LION N/A
  • Fundamental
  • Price
  • BEAM $17.23
  • LION $5.79
  • Analyst Decision
  • BEAM Strong Buy
  • LION Strong Buy
  • Analyst Count
  • BEAM 11
  • LION 6
  • Target Price
  • BEAM $48.90
  • LION $9.58
  • AVG Volume (30 Days)
  • BEAM 1.9M
  • LION 2.4M
  • Earning Date
  • BEAM 08-05-2025
  • LION 08-07-2025
  • Dividend Yield
  • BEAM N/A
  • LION N/A
  • EPS Growth
  • BEAM N/A
  • LION N/A
  • EPS
  • BEAM N/A
  • LION N/A
  • Revenue
  • BEAM $63,578,000.00
  • LION $3,947,900,000.00
  • Revenue This Year
  • BEAM N/A
  • LION N/A
  • Revenue Next Year
  • BEAM $8.82
  • LION $7.02
  • P/E Ratio
  • BEAM N/A
  • LION N/A
  • Revenue Growth
  • BEAM N/A
  • LION N/A
  • 52 Week Low
  • BEAM $13.53
  • LION $5.60
  • 52 Week High
  • BEAM $35.25
  • LION $8.50
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 48.68
  • LION 38.33
  • Support Level
  • BEAM $16.11
  • LION $5.70
  • Resistance Level
  • BEAM $17.38
  • LION $6.20
  • Average True Range (ATR)
  • BEAM 1.02
  • LION 0.24
  • MACD
  • BEAM 0.03
  • LION -0.03
  • Stochastic Oscillator
  • BEAM 30.84
  • LION 22.52

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About LION Lionsgate Studios Corp. Common Shares

Lionsgate Studios Corp is a company encompasses world-class motion picture and television studio operations and the STARZ-branded premium global subscription platforms to bring a unique and varied portfolio of entertainment to consumers around the world. The Studio Business consists of the Motion Picture and Television Production reportable segments, together with substantially all of Lionsgate's corporate general and administrative costs. Motion Picture consists of the development and production of feature films, acquisition of North American and worldwide distribution rights. Television Production consists of the development, production and worldwide distribution of television productions including television series, television movies and mini-series, and non-fiction programming.

Share on Social Networks: